AMPH Earnings

AMPH reported its FY2025Q3 earnings on 2025-11-06, showcasing a revenue of 192.00M against an estimate of 185.00M, resulting in a 3.63% surprise. The EPS was 0.83, surpassing the expected 0.73 by 13.7% . The stock experienced a -0.83% price change on the earnings day and a 14.86% change over the next five days, reflecting market reactions to the results.

Following AMPH's FY2025Q3 earnings announcement on 2025-11-06, the stock price moved by -0.83% on the day of the release. Over the subsequent five days, it saw a 14.86% change. Historically, AMPH's stock price tends to shift by an average of +0.85% in the 10 days leading up to earnings and +5.27% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AMPH’s annual revenue to reach 190.00M, while the EPS is projected at 1.00. These estimates reflect recent revisions, with revenue estimates revised Revenue Revise Upward by 0.18% and EPS estimates Revise Downward by -0.2% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AMPH's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were Revise Upward by 0.18%, while EPS estimates moved Revise Downward by -0.2% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AMPH's stock price typically moves by +0.85% in the 10 days before its earnings and +5.27% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 1.00 and revenue of 190.00M.

The earnings call presents mixed signals. Financial performance shows increased costs and declining margins, but optimistic guidance for future growth. Product development updates are promising, especially with FDA approvals and licensing deals. Market strategy is cautious, focusing on profitability over market share. Expenses show a significant rise, impacting financial health. Shareholder returns are slightly positive with buybacks. The Q&A indicates stable future growth, but management's vague responses about timelines and competition raise concerns. Considering the mid-sized market cap, the stock is likely to experience a neutral reaction, with potential for slight fluctuations.